References
- BanegasJRLopez-GarciaEDallongevilleJAchievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA studyEur Heart J201132172143215221471134
- KahnSEHaffnerSMHeiseMAGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med2006355232427244317145742
- HinklinRJBoydSAChicarelliMJIdentification of a new class of glucokinase activators through structure-based designJ Med Chem201356197669767824015910
- MatschinskyFMAssessing the potential of glucokinase activators in diabetes therapyNat Rev Drug Discov20098539941619373249
- PfefferkornJAStrategies for the design of hepatoselective glucokinase activators to treat type 2 diabetesExpert Opin Drug Discov20138331933023289965
- MatschinskyFMGKAs for diabetes therapy: why no clinically useful drug after two decades of trying?Trends Pharmacol Sci2013342909923305809
- TheodorakisMJCarlsonOMichopoulosSHuman duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIPAm J Physiol Endocrinol Metab20062903E550E55916219666
- DolibaNMFennerDZelentBBassJSarabuRMatschinskyFMRepair of diverse diabetic defects of beta-cells in man and mouse by pharmacological glucokinase activationDiabetes Obes Metab201214Suppl 310911922928571
- MatschinskyFMMagnusonMAGlucokinase and Glycemic Diseases: From Basics to Novel Therapeutics. Frontiers in diabetesBaselKarger2004166574
- MatschinskyFMZelentBDolibaNGlucokinase activators for diabetes therapy: May 2010 status reportDiabetes Care201134Suppl 2S236S24321525462
- FutamuraMYaoJLiXChronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty ratDiabetologia20125541071108022234649
- WeiPShiMBarnumSChoHCarlsonTFraserJDEffects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cellsDiabetologia200952102142215019641898
- ShirakawaJTogashiYSakamotoEGlucokinase activation ameliorates ER stress-induced apoptosis in pancreatic beta-cellsDiabetes201362103448345823801577
- GrimsbyJSarabuRCorbettWLAllosteric activators of glucokinase: potential role in diabetes therapyScience2003301563137037312869762
- ZhuDLDingYHXiaoDWClinically differentiated glucokinase activator HMS5552: effective control of 24 hour glucose and improvement of β cell function in T2DM patientsPoster: 1167-P presented at: The 75th Annual Scientific Sessions of the American Diabetes AssociationJune 5–9, 2015Boston, MA
- DingYHHuPZhuDLClinical observed β-cell function improvement in Chinese T2D patients with 4 week treatment of HMS5552, a novel Glucokinase activatorDiabetes/Metabolism Research and Reviews: Supplement: The 19th Annual Meeting of the Chinese Diabetes SocietyDecember 9–12, 2015Suzhou, People’s Republic of China
- EricssonHRoshammarDWollbrattMTolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clampInt J Pharmacol Ther20125011765777
- MeiningerGEScottRAlbaMEffects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetesDiabetes Care201134122560256621994424
- BonadonnaRCHeiseTArbet-EngelsCPiragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic studyJ Clin Endocrinol Metab201095115028503620739378
- MorrowLALeonsson-ZachrissonMEricssonHSafety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitusDiabetes Obes Metab201214121114112222775976
- Cuesta-MunozALHuopioHOtonkoskiTSevere persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutationDiabetes20045382164216815277402
- LarionMMillerBG23-Residue C-terminal alpha-helix governs kinetic cooperativity in monomeric human glucokinaseBiochemistry200948266157616519473033
- MolnesJTeigenKAukrustIBinding of ATP at the active site of human pancreatic glucokinase – nucleotide-induced conformational changes with possible implications for its kinetic cooperativityFEBS J2011278132372238621569204